Alluvi, known as BI 4744, represents a promising development in weight management care. This dual stimulator targeting both GLP-1 and GIP receptors demonstrates compelling effectiveness in patient trials, possibly https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/